The Disposition of Prasugrel, a Novel Thienopyridine, in Humans

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters et al. · European Heart Journal · 2006 · 536 citations · Full text

Medicine, Cardiology, Pharmacology +17

Structure and Stereochemistry of the Active Metabolite of Clopidogrel

Jean‐Marie Pereillo, Mohamed Maftouh, Alain Andrieu et al. · Drug Metabolism and Disposition · 2002 · 458 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450

Jessica Rehmel, James A. Eckstein, Nagy A. Farid et al. · Drug Metabolism and Disposition · 2006 · 263 citations

Medicine, Biochemistry, Pharmacology +17

The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al. · British Journal of Pharmacology · 2000 · 235 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry

Nagy A. Farid, Fabio Garofolo, Ernest Y. K. Wong et al. · Rapid Communications in Mass Spectrometry · 2006 · 124 citations

Life Sciences, Pharmaceutical Analysis, Pharmacology +17